Stroma-Mediated Breast Cancer Cell Proliferation Indirectly Drives Chemoresistance by Accelerating Tumor Recovery between Chemotherapy Cycles
Daria Miroshnychenko(Moffitt Cancer Center), Andriy Marusyk(Moffitt Cancer Center), Tatiana Miti(Moffitt Cancer Center), Anna Miller(Moffitt Cancer Center), Pragya Kumar(University of South Florida), Nathalia Giraldo(University of South Florida), Philipp M. Altrock(University Hospital Schleswig-Holstein), David Basanta(Moffitt Cancer Center), Mark Laurie(Palo Alto University), Marilyn M. Bui
Cited by 24
Related Papers
Intra-tumour heterogeneity: a looking glass for cancer?
|Nature reviews. Cancer|2012|2k
Tumor heterogeneity: Causes and consequences
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2009|1.6k
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
|Cancer Cell|2020|997
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
|Journal of Clinical Investigation|2011|928
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733